Trial Profile
A First-in-Human, Ascending-Dose Study to Investigate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of a Single, Subcutaneous Dose of LY3209590
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 21 Mar 2023
Price :
$35
*
At a glance
- Drugs Insulin efsitora alfa (Primary) ; Insulin glargine
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; First in man
- Sponsors Eli Lilly and Company
- 20 Mar 2023 Results (From two studies n=73,NCT02942914 and n=33,NCT03367377) assessing safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of basal insulin Fc (BIF; LY3209590) in development for once-weekly dosing for the treatment of patients with diabetes published in the Diabetes, Obesity and Metabolism
- 23 Mar 2021 Results (n=73 (SAD) and n=33 (MAD)) assessing the safety, tolerability, pharmacokinetics, and pharmacodynamics following single and once-weekly doses of basal insulin Fc, presented at the 103rd Annual Meeting of the Endocrine Society.
- 03 Nov 2017 Status changed from recruiting to completed.